Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy.
10.3349/ymj.2016.57.6.1494
- Author:
Hyunju PARK
1
;
Si Hwan KO
;
Jae Myun LEE
;
Jeon Han PARK
;
Youn Hee CHOI
Author Information
1. Department of Physiology, Tissue Injury Defense Research Center, Ewha Womans University School of Medicine, Seoul, Korea. yc@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
PDT;
troglitazone;
apoptosis
- MeSH:
Apoptosis;
Blotting, Western;
Caspase 3;
Cell Death;
Cell Survival;
Colon*;
Colonic Neoplasms*;
Necrosis;
Photochemotherapy*;
Propidium
- From:Yonsei Medical Journal
2016;57(6):1494-1499
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to investigate whether the peroxisomal proliferator-activated receptor gamma (PPARγ) ligand troglitazone in combination with photodynamic therapy (PDT) enhances the apoptotic response of DLD-1 colon cancer cells. MATERIALS AND METHODS: The effects of troglitazone, PDT, and troglitazone in combination with PDT on cell viability and apoptosis were assessed in DLD-1 cells. Cell viability and proliferation were evaluated using the tetrazolium-based MTT assay, and apoptosis was evaluated via cell staining with propidium iodide (PI) and annexin V-FITC. The levels of pro-caspase-3 were measured via Western blot analyses. RESULTS: Treatment of troglitazone and PDT induced the growth retardation and cell death of DLD-1 cells in a dose-dependent manner, respectively. The combination treatment significantly suppressed cell growth and increased the apoptotic response of DLD-1 and resulted in apoptosis rather than necrosis, as shown by PI/annexin V staining and degradation of procaspase-3. CONCLUSION: Conclusion: These results document the anti-proliferative and apoptotic activities of PDT in combination with the PPARγ ligand troglitazone and provide a strong rationale for testing the therapeutic potential of combination treatment in colon cancer.